EU-US collaboration to boost medicine development for rare diseases
New working group will share information and best practices.
The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases.
Click on this link for more information.
